As a record-setting high school runner, Colby Rochford was an anchorman — the guy teammates depended on to take the baton and sprint to victory. These days, while away at college, Rochford is still a young man in a hurry. The opponent now is T-cell lymphoma, and every third Monday, he dashes from class to … Read more
For a long time, the standard treatment for younger patients with newly diagnosed mantle cell lymphoma involved intensive chemotherapy, called induction therapy, followed by autologous stem cell transplant (ASCT, where the patient’s own stem cells are used), followed by maintenance therapy to help keep the cancer from coming back. Based on recent clinical research involving … Read more
Medical advances tend to unfold slowly over many years, fueled by successive clinical studies that build upon each other and together provide the evidence needed to change patient care. A key illustration of this point comes from a recent phase 3 clinical trial, published last October in the New England Journal of Medicine (NEJM), which … Read more
While hematological cancers like leukemia, lymphoma, and multiple myeloma involve white blood cells, other, rarer hematologic malignancies affect red blood cells and platelets. These include polycythemia vera, in which the bone marrow produces too many red blood cells, and essential thrombocythemia, in which platelets levels are abnormally high. Both are chronic diseases that can usually … Read more
Patricia Smith’s experience with cancer will stay with her for the rest of her life. “Walking through deep waters changes you,” she says. “You’re still the same person, but you’re different.” In 2009, Smith was diagnosed with B-cell diffuse lymphoma after she experienced weeks of fatigue and found a lump under her right arm. She … Read more
Follicular lymphoma is a slow-growing form of non-Hodgkin lymphoma (NHL) that arises in white blood cells called B lymphocytes. It’s named for the clumps of abnormal B cells, called follicles, that develop in patients’ lymph nodes. It accounts for 20-30% of all cases of NHL. Although follicular lymphoma currently isn’t curable, patients can live with … Read more
Bispecific antibody therapies are a type of immunotherapy for patients with B-cell non-Hodgkin lymphoma. These therapies provide a valuable new option for patients. There are many standard therapies that are monoclonal antibodies. These therapies treat cancer by binding to a marker on cancer cells and rallying the immune system to destroy them. Bispecific antibodies are … Read more
BCL2 inhibitors are drugs that prompt cancer cells to die by altering the interactions among key proteins within the cells. They were clinically developed, in large part, by researchers at Dana-Farber and have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia … Read more
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma, diagnosed in more than 18,000 people in the U.S. every year. It is a fast-growing lymphoma that can arise in the lymph nodes or, more rarely, in organs such as the spleen, liver, and others. As its name indicates, DLBCL involves the … Read more
Throughout the 20 years Robert Jenkins has been living with follicular lymphoma, he has been through many different treatments — from traditional chemotherapy protocols to innovative approaches like CAR T-cell therapy and bispecific antibodies. His lengthy survivorship has allowed Jenkins to benefit from new advances as they’ve emerged, and along with his wife, Lorna, one … Read more
Hodgkin lymphoma (sometimes called Hodgkin’s lymphoma) is a form of cancer that affects the immune system. It starts in the white blood cells, but what patients and doctors will most likely notice first is a lump in the neck, under the arm, or in the groin. How is Hodgkin lymphoma staged? Hodgkin lymphoma is staged … Read more
For many patients with lymphoma or multiple myeloma, a stem cell transplant with their own stem cells (an autologous transplant) or CAR T-cell therapy can extend life significantly or even cure the disease. A variety of factors influence which of these two treatments is recommended, including: What is the difference between stem cell transplant and … Read more
It may be the quintessential question about cancer therapy: why does a particular treatment work well in some patients and not others with the same disease? The question is especially relevant for immunotherapies known as CAR T-cell therapies precisely because they’re so promising. The therapies, which are made by genetically engineering a patient’s own immune … Read more
Championship rower Dan Lynch is used to fighting against the current. Most people start the sport in their teens or twenties. Lynch dropped oars at 53 on a whim. Today, it isn’t a mere hobby. He’s now pursuing the longest-known streak of consecutive days on an indoor rowing machine. Not even mantle cell lymphoma, a … Read more
What does “refractory” mean medically? The word “refractory” in general use means stubborn or intractable, and in medicine it is specifically applied to disease that does not respond to treatment. Refractory cancer refers to cancer that may be resistant to initial therapy or becomes resistant during treatment. “We would consider disease refractory if doesn’t respond … Read more
Jared Olinski was lifting his four-year-old son off of the floor when he felt three sharp pops in his back followed by pain. At first, cancer wasn’t on his radar. Olinksi was only 35 at the time. “I assumed I pulled a muscle,” Olinski remembers. His primary care physician thought it was a slipped disk … Read more
When John Ferris was first diagnosed with follicular lymphoma in early 2017, he was told he had six to nine months to live. Later, while undergoing treatment that appeared to be halting his cancer, he received an amended diagnosis. “Cancer is not going to kill you, but your drinking could,” his oncologist told Ferris. “We … Read more
Patients with large B-cell lymphoma (LBCL) who did not respond to initial treatment or relapsed within a year may now receive the CAR T-cell product axicabtagene ciloleucel (Yescarta) as a second-line therapy, following approval by the U.S. Food and Drug Administration (FDA) based on results of a recent clinical trial. Until now, the standard of … Read more
As an economist specializing in statistical analysis, Dan Rosenbaum has done everything from help the federal government use more evidence in its decision-making to assist several National Basketball Association (NBA) teams in finding and signing the best players. Research and number-crunching are his expertise, so when Rosenbaum learned he needed a life-saving stem cell transplant … Read more
Born on Jan. 1, Alan Morris is used to sharing a birthday with the New Year. Now the lymphoma patient also has a special day marking what he considers his rebirth — and a harbinger of hope. On Jan. 24, Morris, 58, became the first Dana-Farber Brigham Cancer Center patient to receive outpatient CAR T-cell … Read more